Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients

Novartis International AG / Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores compared to those taking ACE inhibitor enalapril[1]
   

In the overall study population, declines in HRQL scores were associated with an increased risk of worse outcomes, including CV death or heart failure hospitalization, a second analysis reported[2]
 

Findings further support clinical benefits of Entresto and reinforce the urgency to treat appropriate patients with reduced ejection fraction (HFrEF)

Basel, September 19, 2016 - A new post-hoc analysis demonstrates that the decline in health-related quality of life (HRQL) scores associated with a heart failure (HF) hospitalization among patients taking Novartis' Entresto^® (sacubitril/valsartan) was lower - approximately 50% less of a decline - compared to those taking ACE inhibitor enalapril[1]. A second post-hoc analysis in the overall study population shows an association between decline in HRQL score and increased risk of cardiovascular (CV) death and HF hospitalization[2]. The findings are based on data from PARADIGM-HF, the largest clinical trial ever conducted in HF[3], and are being presented at the Heart Failure Society of America (HFSA)'s 20^th Annual Scientific Meeting in Orlando.

"Heart failure hospitalizations can significantly decrease a patient's quality of life and lead to poorer outcomes," said Eldrin F. Lewis, MD, MPH, Associate Physician at Brigham and Women's Hospital and Associate Professor of Medicine, Harvard Medical School. "Heart failure management must focus on strategies to reduce this decline by better managing symptoms which can lead to hospitalization. These analyses suggest that sacubitril-valsartan may help mitigate the impact of heart failure hospitalization on a patient's health-related quality of life, and make a strong case for it as part of optimal treatment of heart failure with reduced ejection fraction."